+7(495)150-11-22 
+7(800)250-87-00 
+7(499)110-40-67 
Molecular Genetic Testing
Appointments for Medical Genetic Consultations by Phone, P. Hertsen Moscow Oncology Research Institute:
A.Tsyb Medical Radiological Research Centre:
N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology:
Specialists at the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation conduct comprehensive examinations of patients to diagnose or rule out cancer.
The clinical and diagnostic departments of NMRRC offer support in examining patients, including those with diagnosed cancer, pre-cancerous conditions, or suspected cancer. The Centre’s high-tech equipment ranks among the best in Russia and meets international standards.
A referral from a physician (or a primary care doctor) is required for diagnostic procedures. We recommend consulting an oncologist at NMRRC, who will advise on the most necessary and informative tests. In complex cases, a team of leading specialists from the Centre can be convened.
MOLECULAR GENETIC TESTING IS AN INTEGRAL PART OF CANCER PATIENT EXAMINATION AND TREATMENT WORLDWIDE
The cause of tumors is genetic mutations, disruptions in one of billions of cells in the human body. These mutations impair normal cell functions, leading to uncontrolled growth, reproduction, and spread (metastasis). However, the presence of such mutations helps distinguish cancer cells from healthy cells, which can guide treatment. With molecular genetic analysis now being a part of clinical practice, it’s possible to analyze a patient’s tumor and create a personalized list of potential target molecules.
Our Molecular Genetic Department provides a full range of modern molecular genetic tests for cancer patients and their relatives.
WHO CAN BENEFIT FROM GENETIC TESTING?
Patients with a cancer diagnosis
Determine cancer predisposition and adjust treatment.
Patients under 50 diagnosed with breast cancer, ovarian cancer, stomach cancer, or pancreatic cancer
Identify cancer predisposition and take preventative measures for early tumor detection.
Healthy individuals with a family history of cancer
Detect cancer predisposition and conduct preventive measures for early tumor detection.
The NMRRC specialists perform a full range of molecular genetic tests required for world-class diagnosis and treatment.
Certain tests may be covered by compulsory medical insurance (OMS) with a referral form 057/u-04.
LIST OF MOLECULAR GENETIC TESTS COVERED BY COMPULSORY MEDICAL INSURANCE
| Name of Genetic test | Group of patients | Biomaterial |
| Molecular genetic testing of mutations in the BRCA1 and BRCA2 genes | Patients with breast and ovarian cancer | Blood* |
| Molecular genetic testing of mutations in the KRAS gene | Patients with colorectal cancer | Paraffin block** |
| Molecular genetic testing of mutations in the NRAS gene | Patients with colorectal cancer | Paraffin block** |
| Molecular genetic testing of mutations in the BRAF gene | Patients with colorectal cancer, melanoma and thyroid cancer | Paraffin block** |
| Microsatellite Instability Detection (MSI) | Any localization | Blood* + Paraffin block** |
| Molecular genetic testing of mutations in the EGFR gene | Patients with various forms of lung cancer | Paraffin block** |
| Molecular genetic testing of mutations in the c-KIT gene | Melanomas and GIST tumors | Paraffin block** |
| Molecular genetic testing of mutations in the PDGFRA gene | GIST tumors | Paraffin block** |
*Blood – whole blood in a vacutainer with EDTA preservative (2 ml)
**Paraffin block – paraffin histological block (formalin-fixed paraffin-embedded tissue). A stained histological preparation obtained directly from the block (coverslip impression) must be applied to the paraffin block. The block number and the number on the coverslip impression must match. It is also possible to work with “microtome sections” from the histological block in an Eppendorf tube, with a volume of 2 µl. (Eppendorf, Safe-Lock Tubes 2.0, Order no: 0030 120.094 or analogue).
CLINICAL RECOMMENDATIONS OF THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION ON MOLECULAR GENETIC DIAGNOSIS IN VARIOUS MALIGNANT NEOPLASMS
- Clinical recommendations «Ovarian cancer/ cervical cancer/ primary peritoneal cancer», ID:KP547/1, year of approval: 2020.
https://cr.minzdrav.gov.ru/recomend/547_2 - Clinical recommendations «Breast cancer», ID:KP379/1, year of approval: 2021.
https://cr.minzdrav.gov.ru/recomend/379_4 - Clinical Recommendations «Pancreatic cancer», ID:KP355/11, year of approval: 2021. https://cr.minzdrav.gov.ru/recomend/355_4
- Clinical recommendations «Prostate cancer», ID:KP12/1, approval year: 2021. https://cr.minzdrav.gov.ru/recomend/12_3
- Clinical recommendations «Malignant neoplasm of bronchus and lung», ID:KP30/1, year of approval: 2021. https://cr.minzdrav.gov.ru/recomend/30_4
- Clinical Recommendations «Skin and mucous membranes melanoma», ID:546/2, year of approval: 2020. https://cr.minzdrav.gov.ru/recomend/546_1
- Clinical Recommendations «Rectal Cancer», ID:KP554/1, Approval Year: 2020, https://cr.minzdrav.gov.ru/recomend/554_3
- Clinical recommendations «Malignant neoplasms of the colon and rectosymoid department», ID:KP396/2, year of approval: 2020. https://cr.minzdrav.gov.ru/recomend/396_1
Clinical Guidelines for Molecular Diagnostics
Size: 25.85 MB
Molecular Genetic Research in Oncology
Size: 18.02 MB
Appointments for Medical Genetic Consultations by Phone: – P. Hertsen Moscow Oncology Research Institute:
A.Tsyb Medical Radiological Research Centre:
N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology:
